We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
High-signal headlines only — macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is one of the 10 Best Penny Stocks to Buy Before They Explode. On May 7, 2026, Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) reported Q1 EPS of (19c), versus the consensus estimate of (15c). Revenue totaled $71.43M, versus the consensus estimate of $75.66M. Interim President and Chief Executive Officer Frederick Vogt said the […]
Iovance Biotherapeutics reported past first-quarter 2026 results with revenue rising to US$71.43 million while net loss narrowed to US$79.05 million, alongside a proposal to lift authorized common shares to 650,000,000. Management highlighted AMTAGVI-driven growth and strengthened guidance supported by improving gross margins and encouraging early data in metastatic serous endometrial cancer, signaling operational and pipeline momentum. Now we’ll examine how this AMTAGVI-fueled revenue jump...
It could just as well drop by 50% -- or more -- over the next 12 months.